Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms
Conditions
Keywords
clinical trial, phase 1, carcinoma, advanced renal cell, kidney, pharmacokinetics, safety, AGS-16M18
Brief summary
This is a first in human study of AGS-16M18 given every week to subjects with advanced renal cell cancer. AGS-16M18 will be administered as a 60 minute IV infusion on consecutive days until the disease worsens.
Detailed description
Subjects will be enrolled sequentially into 5 planned dose cohorts according to a standard, dose escalation study design. A disease assessment will be performed at study week 5 (+/- 3 days) by the investigator. The assessment will be based both on changes in clinical symptoms, and radiographic images. Subjects without evidence of disease progression may receive AGS-16M18 extended therapy at the dose and schedule of their assigned cohort until disease progression or intolerability of AGS-16M18. Disease assessments will be performed every 8 weeks during the extended period. A safety follow-up visit will occur 4 weeks after the last infusion of AGS-16M18.
Interventions
BIOLOGICALAGS-16M18
IV Infusion
Sponsors
Agensys, Inc.
Astellas Pharma Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic or cytologic diagnosis (recent or remote) of metastatic renal cell carcinoma (including papillary, clear cell, and excluding transitional cell types) that is not amendable to cure by surgery or other means, and must have failed at least one prior systemic therapy, including but not limited to treatment with sunitinib, temsirolimus or sorafenib * Evaluable/Measureable disease according to Response Criteria for Solid tumors * Eastern Cooperative Group performance status of 0-1 * Therapeutic anti-coagulation (PT, and/or INR, PTT) permitted, if clinically stable and \>/= 3 months from initiation
Exclusion criteria
* Past or present documented central nervous system (CNS) tumor or CNS metastasis * Use of investigational drug (including marketed drugs not approved for this indication) within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer) * History of thromboembolic events and bleeding disorders \</= 3 months (e.g., DVT or PE) * Major Surgery (that requires general anesthesia) within 4 weeks of study enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events | Throughout the treatment |
| Assessment of PK variables | Weeks 0 - 5, week 8, weekly during extension period, 2 and 3 months after last dose |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of anti-AGS-16M18 antibody formation | Week 0, week 1, week 4, week 8, every 8 weeks during extension period, 2 and 3 months after last dose |
| Changes in tumor status | Week 5, week 8, every 8 weeks during extension period |
Countries
United States
Outcome results
None listed